A patient got the weight loss medication retatrutide before FDA approval. How does that work?

A patient received the weight loss medication retatrutide before it was approved by the U.S. Food and Drug Administration (FDA). This situation raised significant questions about the mechanisms of accessing experimental drugs outside of formal clinical trials. Retatrutide, developed by pharmaceutical giant Eli Lilly, is a weekly injection designed to treat obesity, type 2 diabetes, and several other conditions. While it remains under investigation and has not yet received full FDA approval, it has sparked interest due to its potential for substantial weight loss—some studies suggest participants lost up to 28% of their body weight within two years.

The patient in question—a 79-year-old individual—was granted early access to retatrutide through a process known as "compassionate use." This term refers to a pathway allowing patients with life-threatening illnesses to obtain investigational drugs when standard treatments fail or are unavailable. However, the patient's condition, while severe, was not classified as life-threatening. They suffered from refractory obesity, obstructive sleep apnea, and pulmonary hypertension, all of which can significantly impact quality of life but are not necessarily terminal. Despite this, Dr. Ranganath Muniyappa, a senior NIH clinician, submitted a request for expanded access on behalf of the patient. The request was approved, highlighting the flexibility of compassionate use protocols, even when applied to non-life-threatening conditions.

The method by which the patient accessed retatrutide raises broader concerns about the ethical and regulatory boundaries of drug distribution. Compassionate use is typically reserved for cases involving critical illness, yet the case of the 79-year-old suggests that the criteria may be interpreted more broadly. The patient's identity remained undisclosed, and initial speculation suggested a possible connection to former President Donald Trump, who was also 79 at the time. However, the White House denied this link, emphasizing that the request was unrelated to any political figure.

Meanwhile, the availability of retatrutide has extended beyond controlled clinical settings. In New York City, particularly in Brooklyn, the drug has become a subject of controversy due to its presence in local bodegas. Retailers such as Mr. Green, a convenience store on Bedford Avenue, have begun selling retatrutide without prescriptions, age verification, or medical oversight. These sales occur despite federal regulations prohibiting the commercial sale of unapproved experimental drugs. The drug is often marketed as a weight loss solution, and its popularity has led to widespread demand, even among individuals who may not qualify for compassionate use programs.

The sale of retatrutide in such environments has drawn criticism from medical experts and regulatory bodies. Jonathan Darrow, a drug regulation specialist, expressed surprise at the open marketing of an unapproved product, questioning the justification behind such actions. Similarly, the FDA has issued warnings against purchasing retatrutide labeled for research purposes, citing potential risks to consumer safety. The agency emphasizes that such products lack rigorous testing and may contain contaminants or inaccuracies in labeling.

The manufacturer of the retatrutide sold in bodegas, Indr Labs, has faced scrutiny over the authenticity of its laboratory reports. Certificates of analysis, which are supposed to verify the composition and purity of the drug, have been questioned. For example, one report incorrectly identified the sample as another drug, tirzepatide. Furthermore, the lab associated with these analyses, Vanguard Laboratory, has denied issuing the reports, raising doubts about the reliability of the information provided by Indr Labs. The company has since made changes to its website, requiring passwords to access certain documents, suggesting efforts to obscure transparency.

As the situation unfolds, Eli Lilly continues to push for FDA approval of retatrutide, aiming to bring the drug to market later this year. Meanwhile, regulatory agencies and healthcare professionals remain vigilant about the growing informal distribution of the drug, warning of the potential dangers posed by unregulated access. The case of the 79-year-old patient underscores the complexities of balancing innovation with responsibility, as the lines between therapeutic necessity and speculative use continue to blur.